Clinical trials: Metastasis to Liver
HER2-positive Advanced Solid Tumor
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
- Trial name
- NCT05150691
- Testing
- DB-1303/BNT323, Pertuzumab Injection, Ritonavir
- Where
- 102 sites in United States, Australia and 4 more
- Volunteers
- 796 people
- Sponsor
- DualityBio Inc.
Colorectal Cancer
Resorbable Barrier for the Prevention of Abdominal and Peri-hepatic Adhesion Formation
The purpose of this study is to evaluate the efficiency of a resorbable barrier membrane for the prevention of abdominal and peri-hepatic adhesion in patients with colorectal cancer requiring two-stage surgery for the resection…
- Trial name
- SEPRAC2T (NCT01262417)
- Testing
- - use of resorbable membrane Seprafilm, without resorbable barrier (seprafilm)
- Where
- 17 sites in France
- Volunteers
- 60 people
- Sponsor
- Centre Leon Berard
Uveal Melanoma, Hepatic Metastases
Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
Reports to date show limited efficacy of immunotherapy for uveal melanoma. Recent experimental and clinical evidence suggests synergy between radiation therapy and immunotherapy.
- Trial name
- NCT02913417
- Testing
- SIR-Spheres® Yttrium 90, ipilimumab, nivolumab
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- David Minor, MD
Colorectal Cancer
Treatment of Unresectable Colorectal Metastases by Radiofrequency Ablation Combined or Not With Resection, With or Without Neoadjuvant Chemotherapy.
The hypothesis is that radiofrequency ablation combined or not with resection may allow a local control (the liver) in patients suffering from unresectable colorectal liver metastases.
- Trial name
- ARF2003 (NCT00210106)
- Testing
- Ablathermy
- Where
- 12 sites in France
- Volunteers
- 52 people
- Sponsor
- Institut Bergonié
Liver Cancer, Metastatic Cancer
Cryosurgery in Treating Patients With Liver Cancer or Liver Metastases
RATIONALE: Cryosurgery kills cancer cells by freezing them during surgery. PURPOSE: Phase I/II trial to study the effectiveness of cryosurgery in treating patients with unresectable primary liver cancer or liver metastases.
- Trial name
- NCT00002655
- Testing
- cryosurgery
- Where
- United States
- Sponsor
- University of Colorado, Denver
Liver Cancer, Metastatic Cancer
Quality of Life in Patients With Liver Cancer Treated With Image-Guided Therapy
RATIONALE: Gathering information about quality of life over time from patients with liver cancer treated with image-guided therapy may help the study of cancer in the future.
- Trial name
- NCT00482586
- Testing
- medical chart review, questionnaire administration, quality-of-life assessment
- Where
- 3 sites in United States
- Volunteers
- 137 people
- Sponsor
- Vanderbilt University
Gastric Cancer Metastatic to Liver
Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Gastric Cancer Liver Metastasis (CASTLE-09)
The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Tislelizumab plus Lenvatinib for patients with gastric cancer liver metastasis in the second-/third-Line setting.
- Trial name
- CASTLE-09 (NCT05893056)
- Testing
- Cryoablation, Tislelizumab, Lenvatinib
- Where
- 2 sites in China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Carcinoma, Hepatocellular, Neoplasm Metastasis
Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer
The purpose of this protocol is to provide supervised and limited access to Therasphere® treatment for patients with primary liver cancer and chemotherapy refractory liver metastasis who cannot be treated by surgical removal of…
- Trial name
- NCT00701168
- Testing
- yttrium Y 90 microspheres (Therasphere®)
- Where
- United States
- Sponsor
- Leo W. Jenkins Cancer Center
Colorectal Cancer Liver Metastasis
A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM
The goal of this study is to evaluate the efficacy and safety of multi-mode ablation combined with systemic therapy including PD-1(programmed death receptor 1) inhibitor for colorectal cancer liver metastasis and furthermore to…
- Trial name
- NCT06590259
- Testing
- Multi-mode tumor treatment system, Sintilimab+mFOLFOX6 or FOLFIRI+bevacizumab or cetuximab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai 6th People's Hospital
Uveal Melanoma
Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis
Characterisation of effect of SIRT and DSM-TACE as local treatment options for liver metastases in patients with advanced uveal melanoma with respect to progression-free survival and exploratory comparison of secondary endpoints…
- Trial name
- SirTac (NCT02936388)
- Testing
- SIRT, DSM-TACE
- Where
- Germany
- Volunteers
- 108 people
- Sponsor
- Charite University, Berlin, Germany
Liver Neoplasms, Neoplasm Metastasis
Study of NS-9 in Patients With Liver Metastases
This study is to investigate the safety of NS-9 and to see how well it is tolerated in patients with cancer that has metastasized (spread) to the liver from another primary tumor.
- Conditions
- Liver Neoplasms, Neoplasm Metastasis, Local Neoplasm Recurrences
- Trial name
- NCT00094003
- Testing
- NS-9 [Poly I: Poly C]
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- NS Pharma, Inc.
Colorectal Cancer, KRAS Wildtype
Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients
Up to 50% of patients with colorectal cancer (CRC) develop liver metastasis during the course of their disease. In 30-40% of patients metastasis is confined to the liver.
- Conditions
- Colorectal Cancer, KRAS Wildtype, After Resection of Liver Metastases
- Trial name
- NCT01384994
- Testing
- Folic Acid, 5-FU, Oxaliplatin
- Where
- Germany
- Volunteers
- 111 people
- Sponsor
- PD Dr. med. Volker Heinemann
Cholecystitis, Hepatocellular Carcinoma
Low Dose ICG for Biliary Tract and Tumor Imaging
Near-infrared fluorescence (NIRF) imaging after an intravenous injection of indocyanine green (ICG) allows for the intraoperative identification of liver anatomy.
- Conditions
- Cholecystitis, Hepatocellular Carcinoma, Liver Metastases
- Trial name
- ICG (NCT04942665)
- Testing
- Indocyanine green, PINPOINT Endoscopic Fluorescence
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Florida
Colorectal Cancer With Hepatic Metastases, Pancreas Cancer With Hepatic Metastase
TKM 080301 for Primary or Secondary Liver Cancer
Background: Cancer in the liver can start in the liver (e.g., primary liver cancer or hepatocellular cancer) or spread to the liver from cancers in other parts of the body (e.g.
- Conditions
- Colorectal Cancer With Hepatic Metastases, Pancreas Cancer With Hepatic Metastase, Gastric Cancer With Hepatic Metastase, Breast Cancer With Hepatic Metastase
- Trial name
- NCT01437007
- Testing
- TKM-080301
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Colorectal Neoplasms Malignant
Simultaneous vs. Staged Resection of Colorectal Cancer With Synchronous Liver Metastases
The SYLMET Trial is a randomized trial to compare simultaneous and two-staged resection of primary colorectal and synchronous liver metastases.
- Conditions
- Colorectal Cancer, Colorectal Neoplasms Malignant, Liver Metastasis Colon Cancer, Liver Metastases
- Trial name
- SYLMET (NCT06200831)
- Testing
- Staged resection, Simultaneous resection
- Where
- Norway
- Volunteers
- 80 people
- Sponsor
- Oslo University Hospital
Metastatic Colorectal Carcinoma (mCRC), Metastatic Liver Cancer
Streamlining Radioembolization for CCC and Metastatic Liver Cancer
TARE uses radioactive microspheres (20-60 μm), which are trapped in tumors due to abnormal vasculature, while normal liver sinusoids (≤15 μm) prevent their passage.
- Conditions
- Metastatic Colorectal Carcinoma (mCRC), Metastatic Liver Cancer, Cholangiocarcinoma
- Trial name
- ISTAR-03 (NCT07043387)
- Where
- 4 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver
HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization
This phase IIb trial tests the effect of HRX215 in treating patients with colorectal cancer that has spread from where it first started to the liver (liver metastasis) after undergoing a portal vein embolization (PVE).
- Conditions
- Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Resectable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
- Trial name
- NCT07612007
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Mayo Clinic
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver
CCR5 Targeting Leronlimab in Combination With Hepatic Arterial Infusion Floxuridine and Systemic Therapy for the Treatment of Colorectal Cancer Liver Metastases, CHAMP Trial
This phase I/Ib trial tests the effect of leronlimab in combination with hepatic arterial infusion (HAI) floxuridine (FUDR)and standard of care (SOC) systemic therapy in treating patients with colorectal cancer that has spread…
- Conditions
- Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8
- Trial name
- NCT07842965
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- City of Hope Medical Center
Colon Cancer
Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients
The goal of this clinical trial is to learn about efficacy of Rimegepant in combination with PD-1 in patients with liver metastasis colorectal cancer.
- Trial name
- NCT06999252
- Testing
- Rimegepant, PD-1
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fudan University
Steatohepatitis
PET-MR Study of Fatty Liver
This is a pilot, translational study designed to explore the feasibility of molecular imaging with FBA-A20FMDV2, radiolabelled with fluorine-18 ([18F]-FBA-A20FMDV2), in patients with SH and CASH in hepatic metastatic disease.
- Trial name
- iDOSH (NCT04063826)
- Testing
- PET MRI
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Imperial College London
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.